Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 220 participants.
Also called NCT04634916
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 220 participants
- Sponsor
- Registry
-
NCT04634916
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Australia
- Registry status
- Recruiting
Technical summary
Registry record NCT04634916. Allocation not applicable; no masking; primary purpose treatment. Start 2021-03-26 (actual); primary completion 2027-06 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
- Acronym
- CONNECT-AV
- Condition
- Kidney Disease, End-Stage
- Condition
- End-stage Renal Disease
- Condition
- Arteriovenous Fistula
- Intervention (Device)
- EndoAVF Creation
- Lead sponsor
- C. R. Bard
Record details
- Record id
cardio:ct-nct04634916- Content hash
757755114f2467c0919de83a220ae1b0e6e3721b191478aa145ccebc1d2621a3